199 related articles for article (PubMed ID: 25851955)
1. Assessing the treatment effect in a randomized controlled trial with extensive non-adherence: the EVOLVE trial.
Kubo Y; Sterling LR; Parfrey PS; Gill K; Mahaffey KW; Gioni I; Trotman ML; Dehmel B; Chertow GM
Pharm Stat; 2015; 14(3):242-51. PubMed ID: 25851955
[TBL] [Abstract][Full Text] [Related]
2. Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) trial.
Wheeler DC; London GM; Parfrey PS; Block GA; Correa-Rotter R; Dehmel B; Drüeke TB; Floege J; Kubo Y; Mahaffey KW; Goodman WG; Moe SM; Trotman ML; Abdalla S; Chertow GM; Herzog CA;
J Am Heart Assoc; 2014 Nov; 3(6):e001363. PubMed ID: 25404192
[TBL] [Abstract][Full Text] [Related]
3. Economic Evaluation of Cinacalcet in the United States: The EVOLVE Trial.
Belozeroff V; Chertow GM; Graham CN; Dehmel B; Parfrey PS; Briggs AH
Value Health; 2015 Dec; 18(8):1079-87. PubMed ID: 26686794
[TBL] [Abstract][Full Text] [Related]
4. The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.
Parfrey PS; Drüeke TB; Block GA; Correa-Rotter R; Floege J; Herzog CA; London GM; Mahaffey KW; Moe SM; Wheeler DC; Kubo Y; Dehmel B; Goodman WG; Chertow GM;
Clin J Am Soc Nephrol; 2015 May; 10(5):791-9. PubMed ID: 25710802
[TBL] [Abstract][Full Text] [Related]
5. Lessons Learned from EVOLVE for Planning of Future Randomized Trials in Patients on Dialysis.
Parfrey PS; Block GA; Correa-Rotter R; Drüeke TB; Floege J; Herzog CA; London GM; Mahaffey KW; Moe SM; Wheeler DC; Chertow GM
Clin J Am Soc Nephrol; 2016 Mar; 11(3):539-46. PubMed ID: 26614406
[TBL] [Abstract][Full Text] [Related]
6. The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial.
Parfrey PS; Chertow GM; Block GA; Correa-Rotter R; Drüeke TB; Floege J; Herzog CA; London GM; Mahaffey KW; Moe SM; Wheeler DC; Dehmel B; Trotman ML; Modafferi DM; Goodman WG
J Clin Endocrinol Metab; 2013 Dec; 98(12):4834-44. PubMed ID: 24108314
[TBL] [Abstract][Full Text] [Related]
7. Cinacalcet and Clinical Outcomes in Dialysis.
Komaba H; Fukagawa M
Semin Dial; 2015; 28(6):594-603. PubMed ID: 26265359
[TBL] [Abstract][Full Text] [Related]
8. Estimating the Effect of Preventable Treatment Discontinuation on Health Outcomes.
Brookhart MA; Reams D; Dluzniewski PJ; Kshirsagar A; Walsh L; Bradbury BD
Epidemiology; 2018 Jan; 29(1):134-141. PubMed ID: 28991002
[TBL] [Abstract][Full Text] [Related]
9. Analyzing Health-Related Quality of Life in the EVOLVE Trial: The Joint Impact of Treatment and Clinical Events.
Briggs AH; Parfrey PS; Khan N; Tseng S; Dehmel B; Kubo Y; Chertow GM; Belozeroff V
Med Decis Making; 2016 Nov; 36(8):965-72. PubMed ID: 26987347
[TBL] [Abstract][Full Text] [Related]
10. The effects of cinacalcet on blood pressure, mortality and cardiovascular endpoints in the EVOLVE trial.
Chang TI; Abdalla S; London GM; Block GA; Correa-Rotter R; Drüeke TB; Floege J; Herzog CA; Mahaffey KW; Moe SM; Parfrey PS; Wheeler DC; Dehmel B; Goodman WG; Chertow GM
J Hum Hypertens; 2016 Mar; 30(3):204-9. PubMed ID: 26040438
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview.
Chertow GM; Pupim LB; Block GA; Correa-Rotter R; Drueke TB; Floege J; Goodman WG; London GM; Mahaffey KW; Moe SM; Wheeler DC; Albizem M; Olson K; Klassen P; Parfrey P
Clin J Am Soc Nephrol; 2007 Sep; 2(5):898-905. PubMed ID: 17702710
[TBL] [Abstract][Full Text] [Related]
12. Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE Trial.
Moe SM; Abdalla S; Chertow GM; Parfrey PS; Block GA; Correa-Rotter R; Floege J; Herzog CA; London GM; Mahaffey KW; Wheeler DC; Dehmel B; Goodman WG; Drüeke TB;
J Am Soc Nephrol; 2015 Jun; 26(6):1466-75. PubMed ID: 25505257
[TBL] [Abstract][Full Text] [Related]
13. Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.
Moe SM; Chertow GM; Parfrey PS; Kubo Y; Block GA; Correa-Rotter R; Drüeke TB; Herzog CA; London GM; Mahaffey KW; Wheeler DC; Stolina M; Dehmel B; Goodman WG; Floege J;
Circulation; 2015 Jul; 132(1):27-39. PubMed ID: 26059012
[TBL] [Abstract][Full Text] [Related]
14. Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial.
Chertow GM; Correa-Rotter R; Block GA; Drueke TB; Floege J; Goodman WG; Herzog CA; Kubo Y; London GM; Mahaffey KW; Mix TC; Moe SM; Wheeler DC; Parfrey PS
Nephrol Dial Transplant; 2012 Jul; 27(7):2872-9. PubMed ID: 22529163
[TBL] [Abstract][Full Text] [Related]
15. Propensity score matching and persistence correction to reduce bias in comparative effectiveness: the effect of cinacalcet use on all-cause mortality.
Gillespie IA; Floege J; Gioni I; Drüeke TB; de Francisco AL; Anker SD; Kubo Y; Wheeler DC; Froissart M;
Pharmacoepidemiol Drug Saf; 2015 Jul; 24(7):738-47. PubMed ID: 26011775
[TBL] [Abstract][Full Text] [Related]
16. Randomized controlled trials 6: On contamination and estimating the actual treatment effect.
Parfrey PS
Methods Mol Biol; 2015; 1281():249-59. PubMed ID: 25694314
[TBL] [Abstract][Full Text] [Related]
17. Randomized Controlled Trials 7: On Contamination and Estimating the Actual Treatment Effect.
Parfrey PS
Methods Mol Biol; 2021; 2249():307-318. PubMed ID: 33871851
[TBL] [Abstract][Full Text] [Related]
18. What can we learn from a statistically inconclusive trial? Consensus conference on the EVOLVE study results.
Locatelli F; Messa P; Bellasi A; Cozzolino M; Di Luca M; Garibotto G; Gesualdo L; Malberti F; Massimetti C; Mazzaferro S; Mereu MC; Morosetti M; Morrone LF; Panuccio V; Rapisarda F; Russo D; Schinella D
G Ital Nefrol; 2013; 30(5):. PubMed ID: 24402624
[TBL] [Abstract][Full Text] [Related]
19. [The effect of oral calcimimetics on cardiovascular events.].
Hamano T
Clin Calcium; 2017; 27(4):529-535. PubMed ID: 28336829
[TBL] [Abstract][Full Text] [Related]
20. The win ratio approach to analyzing composite outcomes: An application to the EVOLVE trial.
Abdalla S; Montez-Rath ME; Parfrey PS; Chertow GM
Contemp Clin Trials; 2016 May; 48():119-24. PubMed ID: 27080930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
